Information Provided By: 
Fly News Breaks for February 12, 2020
CRL
Feb 12, 2020 | 06:30 EDT
Citi analyst Patrick Donnelly raised his price target for Charles River Laboratories to $200 from $185 saying the company posted strong Q4 results and provided guidance well above Street expectations. Management was constructive on the biopharma funding environment heading into 2020, and laid out a number of drivers that should facilitate sales growth and margin expansion near the top end of the peer group, Donnelly tells investors in a research note. He reiterates a Buy rating on Charles River shares.
News For CRL From the Last 2 Days
There are no results for your query CRL
